RASEF

Across TCGA pan-cancer cohorts, RASEF mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RASEF data layer compared with 25 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher RASEF mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RASEF expression acts as an unfavorable survival marker.

CCRCC, LUAD, and PDAC are the cancer types where RASEF mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.080	1.000	.038	6	view →
LUAD	DFS	Median	III,IV	0.409	0.941	.010	4	view →
PDAC	OS	Tertile	III,IV	0.344	1.000	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

RASEF–CCRCC (OS)

Open the CCRCC breakdown →